A compositions comprising a protein, a protease inhibitor and N-(8-[2-hydroxybenzoyl]amino)caprylate (SNAC) or N-(10[2-hydroxybenzoyl]amino)decanoate (SNAD) for diabetes mellitus treatment
Disclosed is a solid oral pharmaceutical composition comprising a protein having a molecular weight of up to 100,000 Daltons； a protease inhibitor being a trypsin inhibitor； and a compound selected from the group consisting of N-(8-[2- hydroxybenzoyl]amino)caprylate (SNAC), a salt of said SNAC and a combination thereof, the composition being useful for delivering said protein through a biological, chemical, and/or physical barrier of a subject such that a substantial fraction of said protein retains its activity after absorption through said barrier.
